Last reviewed · How we verify
NCT03933345
Overdose Risk Management and Naloxone
trial testing Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control. in Opioid Use in 600 participants. Status unknown.
1 August 2022
Quick facts
| Lead sponsor | National Development and Research Institutes, Inc. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 5 April 2019 |
| Primary completion | 1 August 2022 |
| Estimated completion | 31 August 2023 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.
Conditions studied
- Opioid Use — all drugs for Opioid Use →
Sponsor
National Development and Research Institutes, Inc.
Who can join
18 and older, any sex, with Opioid Use. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A growing body of research underscores the life- and cost-saving advantages of equipping people who use opioids with naloxone, but very little is known about: 1) barriers to naloxone awareness and access, and 2) the potential psychosocial and behavioral impacts of being "protected" by naloxone while engaging in overdose risk behaviors, of using naloxone on someone else, and of surviving an overdose in which naloxone is used. This research will provide insight into both of these domains to yield a richly contextualized understanding of the processes and mechanisms underlying changes in overdose risk behaviors related to naloxone access and use and will illuminate the disparities that may limit access to naloxone for some or result in compensatory behavior following naloxone exposure for others. Findings from this study will provide an empirical basis to strengthen and refine existing overdose prevention efforts and to design tailored interventions to engage opioid users who have recently survived or reversed an overdose.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Nanotechnology-Enhanced Naloxone and Alternative Treatments for Opioid Addiction.
Heyns IM, Faunce AF, Mumba MN, Kumar MNVR, et al · · 2024 · cited 2× · PMID 39144549 · DOI 10.1021/acsptsci.4c00158
Verify or expand the search:
- PubMed search for NCT03933345
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid Use
Currently open trials in the same condition.
- NCT07342504 — Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist · NA · recruiting
- NCT07004686 — Effect of MGRNOX-Guided General Anesthesia on Opioid Consumption in Patients · NA · recruiting
- NCT06981195 — Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects · Phase 2 · recruiting
- NCT06806163 — Machine-Learning Prediction and Reducing Overdoses With EHR Nudges · NA · recruiting
- NCT06909851 — Comparison of Pain Relief After Arthroscopic Knee Surgery: Adductor Canal Block and Genicular Nerve Block · NA · recruiting
Other National Development and Research Institutes, Inc. trials
Trials by the same sponsor.
- NCT03418636 — The Staying Safe Intervention · NA · unknown
- NCT03610672 — Mobile Intervention for Young Opioid Users · NA · unknown
- NCT02760628 — The First Twenty (TF20) for Volunteer Firefighters in a Clinic Based Setting · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03933345 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Development and Research Institutes, Inc.
- Last refreshed: 1 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03933345.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing